Last reviewed · How we verify
Acarizax
Acarizax is a Small molecule drug developed by University Hospital, Montpellier. It is currently in Phase 3 development.
Acarizax is a sublingual allergy immunological tablet used to treat conditions such as allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma due to house dust mites. It is specifically indicated for allergic reactions caused by the droppings of house dust mites, which contain potent digestive enzymes that can trigger symptoms like wheezing.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Acarizax |
|---|---|
| Sponsor | University Hospital, Montpellier |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65 (PHASE3)
- Identification of B Regulatory Cells by Flow Cytometry
- Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab (PHASE3)
- Microbial Study of Sublingual Immunotherapy Tablets in Patients With Allergic Rhinitis
- Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy (PHASE2)
- Dupilumab and House Dust Mite Immunotherapy in Patients With Atopic Dermatitis (NA)
- House Dust Mite Allergy Trial In Children (PHASE3)
- Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acarizax CI brief — competitive landscape report
- Acarizax updates RSS · CI watch RSS
- University Hospital, Montpellier portfolio CI
Frequently asked questions about Acarizax
What is Acarizax?
Who makes Acarizax?
What development phase is Acarizax in?
Related
- Manufacturer: University Hospital, Montpellier — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing